Aclaris Therapeutics (NASDAQ:ACRS) had its price target decreased by investment analysts at Cantor Fitzgerald from $50.00 to $24.00 in a note issued to investors on Wednesday, The Fly reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 418.36% from the company’s previous close.
ACRS has been the subject of a number of other reports. Zacks Investment Research lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 21st. BidaskClub upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 8th. Finally, ValuEngine raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Aclaris Therapeutics has a consensus rating of “Hold” and an average target price of $19.69.
ACRS traded down $0.18 during trading on Wednesday, hitting $4.63. The company had a trading volume of 14,522 shares, compared to its average volume of 515,834. The stock has a market capitalization of $200.16 million, a PE ratio of -1.16 and a beta of 1.48. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.33 and a quick ratio of 4.30. Aclaris Therapeutics has a 1-year low of $4.27 and a 1-year high of $21.97.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.05). Aclaris Therapeutics had a negative net margin of 999.53% and a negative return on equity of 78.05%. The company had revenue of $5.04 million during the quarter, compared to analyst estimates of $5.13 million. On average, equities research analysts forecast that Aclaris Therapeutics will post -2.98 earnings per share for the current fiscal year.
In other news, major shareholder James E. Flynn sold 614,710 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $6.13, for a total transaction of $3,768,172.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 14.80% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Citigroup Inc. lifted its position in shares of Aclaris Therapeutics by 3,200.0% during the 4th quarter. Citigroup Inc. now owns 3,993 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 3,872 shares during the period. Great West Life Assurance Co. Can bought a new stake in shares of Aclaris Therapeutics during the 4th quarter worth $43,000. BNP Paribas Arbitrage SA lifted its position in shares of Aclaris Therapeutics by 82,200.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,407 shares of the biotechnology company’s stock worth $44,000 after buying an additional 7,398 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Aclaris Therapeutics by 64.1% during the 4th quarter. Legal & General Group Plc now owns 6,495 shares of the biotechnology company’s stock worth $48,000 after buying an additional 2,536 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Aclaris Therapeutics during the 1st quarter worth $70,000. Hedge funds and other institutional investors own 91.79% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
Featured Story: Cost of Debt
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.